Differences in immune-related semaphorin levels in the CSF and serum of newly diagnosed, treatment-naive patients with relapsing–remitting multiple sclerosis: a case–control study - Quiz - MDSpire

Differences in immune-related semaphorin levels in the CSF and serum of newly diagnosed, treatment-naive patients with relapsing–remitting multiple sclerosis: a case–control study

  • By

  • Furkan Sarıdaş

  • Birnur Aydın

  • Rifat Özpar

  • Emine Rabia Koç

  • Bahattin Hakyemez

  • Tülin Alkan

  • Ömer Faruk Turan

  • July 14, 2026

Share

Original Source(s)

Differences in immune-related semaphorin levels in the CSF and serum of newly diagnosed, treatment-naive patients with relapsing–remitting multiple sclerosis: a case–control study

  • by Furkan Sarıdaş, Birnur Aydın, Rifat Özpar, Emine Rabia Koç, Bahattin Hakyemez, Tülin Alkan, Ömer Faruk Turan

  • July 14, 2026

Related Content

Non-Linear Measures of Movement Variability in Multiple Sclerosis: A Clinical Narrative Review of Lyapunov Exponent and Entropy Applications in Balance and Gait

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.